Sturdy monetary momentum: Viemed reported >172,000 sufferers, a 26% CAGR since going public, $270M income and $28M free money movement in 2025, stays web debt-free, and guided 2026 income of $310–$320M with EBITDA of $65–$69M.
Fast diversification away from ventilators: Air flow fell from 87% of income in 2019 to 48% in the present day as sleep (now 21% of web income), oxygen, airway clearance, maternal well being and staffing have expanded—CPAP affected person development rose 62% in 2025 and administration is “doubling down” on sleep.
Giant underserved market and bettering regulatory backdrop: Administration cites roughly 1.25M Medicare candidates for advanced respiratory care however solely ~70,000 handled (≈6% penetration), and famous favorable coverage strikes together with a brand new ventilator NCD and CMS exclusions from aggressive bidding that scale back reimbursement uncertainty.
Viemed Healthcare (NASDAQ:VMD) executives outlined the corporate’s home-based respiratory care mannequin, current monetary efficiency, and development priorities throughout a current investor presentation, emphasizing an increasing service combine, continued natural development, and what administration characterised as an bettering regulatory backdrop.
Administration stated Viemed focuses on treating advanced respiratory sufferers within the residence, aiming to cut back emergency room visits and hospitalizations and assist hospitals handle readmissions and size of keep. The corporate stated it serves as a hyperlink between payers, physicians, and sufferers by navigating care supply within the residence utilizing a mix of in-home expertise and respiratory therapist help.
Viemed reported having greater than 172,000 sufferers below care throughout all 50 states, with what it described as “first rate protection” in roughly 37 to 38 states and extra room to densify and increase geographically. The corporate stated it has grown at a 26% compound annual development charge since going public and generated $28 million of free money movement in 2025 whereas sustaining no web debt.
On its core ventilator providing, administration stated the month-to-month reimbursement is about $1,050 from Medicare, with most personal insurers following an identical mannequin. The corporate described the reimbursement construction as an “uncapped rental” bundled charge that features 24/7 in-home respiratory care, provides, and tools. Executives cited a median affected person size of keep of 17 months, noting affected person length can range.
Administration highlighted what it sees as a big underserved COPD inhabitants. Executives stated the U.S. has about 25 million individuals with COPD, with about 10%—or 2.5 million—on the most extreme degree. Viemed estimated roughly half of these extreme instances attain continual respiratory failure and turn into candidates for advanced respiratory companies. The corporate stated there are about 1.25 million such sufferers in Medicare, whereas the trade has handled about 70,000 Medicare beneficiaries, which administration characterised as roughly 6% penetration in Medicare and “sub-10%” when together with personal insurance coverage. Viemed stated it’s the third-largest supplier within the area, representing about 14% market share, and that the highest 10 suppliers comprise 62% of the market.
Viemed stated it makes use of in-house expertise deployed in sufferers’ houses, together with a pill interface that connects to ventilators and different tools, permits distant readings, and helps telehealth interactions with respiratory therapists throughout episodes comparable to shortness-of-breath assaults. Administration stated the corporate captures information and outcomes to report again to physicians and payers.
Executives additionally referenced three research the corporate has accomplished within the area, citing themes that embrace decreased emergency room visits and hospitalizations. Administration stated the research confirmed a 43% relative mortality discount and a 39% relative discount in all-cause mortality over seven years, and urged potential financial savings of greater than $5,400 per affected person per yr by initiating therapies earlier.
The corporate described its working mannequin as lean and scalable, emphasizing that it doesn’t usually require a conventional sturdy medical tools (DME) footprint comparable to retail shops. As an alternative, it depends on a cell workforce, with therapists carrying stock of their automobiles and utilizing information to focus on “COPD needy wealthy environments” based mostly on prevalence and readmission patterns.
Administration stated it has broadened its service combine lately, including platforms in sleep, maternal well being, and staffing alongside advanced respiratory companies. Viemed listed further choices that embrace airway clearance units (comparable to percussion vests), stationary and moveable oxygen concentrators, sleep apnea CPAP remedy with recurring resupply income, and breast pumps.
Executives mentioned a July 1 acquisition of Lehan’s Medical in Illinois, describing it as 60% maternal well being and 40% respiratory, and stated the corporate is including breast pumps and expects maternal well being to increase in 2026 and past.
Administration introduced a income combine shift from 2019 to the present interval, stating that air flow represented 87% of income in 2019 and is now 48%. The corporate stated oxygen represents 8% of income, airway clearance 7%, sleep 21%, maternal well being 6%, and healthcare staffing 8%.
On sleep, administration described it as one of many firm’s fastest-growing segments. Executives stated that in 2025 CPAP affected person development elevated 62% and resupply grew 49%, with sleep reaching 21% of web income by the fourth quarter of 2025. The corporate attributed sleep development to acquisitions, salesforce enlargement, and demand for sleep apnea remedy, and stated it’s “doubling down” on sleep in 2026. Administration put the addressable U.S. sleep market at greater than 30 million sufferers.
The staffing enterprise, which administration stated was added post-COVID amid a scientific labor scarcity, has advanced into state-by-state contracts. Executives stated about 80% of staffing now has a behavioral well being part, together with putting licensed scientific social staff for particular tasks.
In a evaluation of 2025 efficiency, administration stated Viemed ended the yr with simply over $270 million in income and over $60 million of EBITDA. Executives stated the corporate stays web debt-free, with roughly as a lot money as debt, and famous it has been paying down debt taken on for the Lehan’s acquisition.
Administration additionally mentioned buybacks, stating the corporate executed its third repurchase program final yr and acquired again 5% of fairness. Executives stated Viemed has repurchased 4.5 million shares at a median worth of $5.79 and not too long ago launched one other buyback.
For 2026, administration offered steerage of $310 million to $320 million in income and $65 million to $69 million of EBITDA. Executives stated EBITDA development trails income partly as a result of 2025 included a number of million {dollars} of beneficial properties associated to a ventilator buyback program. Administration stated gross margins have compressed barely over time resulting from diversification throughout product traces, whereas EBITDA margins have been comparatively secure. The corporate additionally stated it has been worthwhile on a web earnings foundation yearly since going public.
Executives stated most development has been natural, estimating that of the $270 million in 2025 income, roughly $50 million was acquired. They described Viemed as “sales-driven,” targeted on recruiting salespeople and therapists in underserved markets, whereas additionally pursuing disciplined M&A with administration groups that may assist increase product traces or enhance advanced respiratory capabilities.
Administration stated it’s utilizing AI instruments throughout departments and expects this to sluggish the tempo of future hiring. Executives additionally emphasised declining capital expenditure depth, noting the ventilator enterprise—traditionally the best CapEx space—has matured as the corporate reaches roughly 12,000 to 13,000 lively ventilator sufferers. They stated development in CPAP resupply and maternal well being is relatively low- to zero-CapEx, supporting expectations for larger free money movement past the $28 million generated in 2025.
Administration highlighted what it described as supportive regulatory tailwinds towards home-based care and cited demographic traits, together with an estimated 10,000 child boomers turning 65 every day by way of 2030. Executives additionally stated CMS has indicated that the merchandise Viemed presents will likely be excluded from aggressive bidding, which administration stated reduces uncertainty for traders.
The corporate mentioned a brand new ventilator Nationwide Protection Willpower (NCD) introduced in June, describing it as offering clearer guidelines and lowering ambiguity round protection necessities. Administration stated this readability might help forestall denials from Medicare Benefit plans and that the corporate is already seeing a behavioral shift from payers.
On reimbursement traits, executives stated current adjustments have largely been CPI-linked will increase. They cited traditionally larger CPI bumps following COVID (together with 5% and eight% in sure durations) and stated the present yr’s enhance is roughly 2% to 2.8% relying on product and geography, with expectations for an additional CPI adjustment heading into 2027.
Viemed Healthcare, Inc (NASDAQ: VMD) is a supplier of home-based respiratory remedy companies, specializing within the administration of sufferers requiring long-term mechanical air flow and pulmonary help. The corporate’s choices embody invasive and noninvasive air flow, airway clearance therapies, cough help units, and supplemental oxygen. Viemed combines sturdy medical tools with scientific care, delivering tailor-made respiratory remedy plans which can be overseen by licensed respiratory therapists and registered nurses.
Based within the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve sufferers throughout a number of states in the USA.
